89Bio Investor Relations Material
Latest events
Status Update
89Bio
Q1 2025
1 May, 2025
Q4 2024
27 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from 89Bio Inc
Access all reports
89Bio Inc is a clinical-stage biopharmaceutical company focused to the development and commercialization of therapies aimed at treating liver and cardio-metabolic diseases. The company is building a pipeline that includes biologic and small molecule treatments, focusing on addressing unmet medical needs in these therapeutic areas. The company is headquartered in San Francisco, California, and its shares are listed on the NASDAQ under the symbol ETNB.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
ETNB
Country
🇺🇸 United States